ShangPharma Partners with Scripps Research to Form $15 Million US Accelerator
publication date: Jun 9, 2017
ShangPharma Innovation, the US-based biopharma incubator arm of China CRO ShangPharma, will collaborate with The Scripps Research Institute (TSRI) and its drug discovery affiliate, California Institute for Biomedical Research (Calibr), to accelerate the development of innovative drug candidates. ShangPharma will contribute $15 million in funding and in-kind services over three years. TSRI/Calibr will suggest promising drug candidates. TSRI/Calibr will own rights to the projects, while ShangPharma will receive a portion of any proceeds they may produce. TSRI and Calibr are both located in La Jolla, California. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.